Alectinib after failure to crizotinib in patients with ALK-positive non-small cell lung cancer: results from the Spanish early access program-Reference-Cited by-同舟云学术

Alectinib after failure to crizotinib in patients with ALK-positive non-small cell lung cancer: results from the Spanish early access program

Published:2022-06-15 Issue:1 Volume:13 Page:812-827
ISSN:1949-2553
Container-title:Oncotarget
language:en
Short-container-title:Oncotarget

Author:

Bernabé-Caro Reyes¹,Garrido Pilar²,García-Campelo Rosario³,Palmero Ramón⁴,Artal Ángel⁵,Bayona Cristina⁶,Rodríguez-Abreu Delvys⁷,López-Brea Marta⁸,Paredes Alfredo⁹,Vicente David¹⁰,Sánchez Torres José Miguel¹¹,Majem Margarita¹²,Diz Pilar¹³,Gordo Rocío¹⁴,Coca Margarita¹⁴,de Castro Javier¹⁵

Affiliation:

1. Department of Medical Oncology, Hospital Virgen del Rocío, Sevilla, Spain

2. Department of Medical Oncology, Hospital Universitario Ramon y Cajal, Madrid, Spain

3. Department of Medical Oncology, Hospital Universitario A Coruña, A Coruña, Spain

4. Department of Medical Oncology, ICO Bellvitge, Hospitalet Llobregat, Barcelona, Spain

5. Department of Medical Oncology, Hospital Universitario Miguel Servet, Zaragoza, Spain

6. Department of Medical Oncology, Hospital General Yague, Burgos, Spain

7. Department of Medical Oncology, Hospital Insular de Gran Canaria, Las Palmas de Gran Canaria, Spain

8. Department of Medical Oncology, Hospital Marqués de Valdecilla, Santander, Spain

9. Department of Medical Oncology, Hospital Universitario Donostia, Donostia-San Sebastián, Spain

10. Department of Medical Oncology, Hospital Universitario Virgen Macarena, Sevilla, Spain

11. Department of Medical Oncology, Hospital Universitario La Princesa, Madrid, Spain

12. Department of Medical Oncology, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain

13. Department of Medical Oncology, Complejo Asistencial Universitario de León, León, Spain

14. Roche Farma, S.A., Madrid, Spain

15. Department of Medical Oncology, Hospital Universitario La Paz, Madrid, Spain

Publisher

Impact Journals, LLC

Subject

Oncology

Reference44 articles.

1. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer;Ishikawa;Nature,2007

2. Extended Survival and Prognostic Factors for Patients With ALK-Rearranged Non-Small-Cell Lung Cancer and Brain Metastasis;Kavanagh;J Clin Oncol,2016

3. Brain metastases in patients with EGFR-mutated or ALK-rearranged non-small-cell lung cancers;Costa;Lung Cancer,2015

4. Insights into brain metastasis in patients with ALK+ lung cancer: is the brain truly a sanctuary?;Ichinose;Cancer Metastasis Rev,2015

5. First-line crizotinib versus chemotherapy in ALK-positive lung cancer;Wilner;N Engl J Med,2014

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Advancements in the diagnosis and treatment of sub‑centimeter lung cancer in the era of precision medicine (Review);Molecular and Clinical Oncology;2024-02-09

2. Clinical significance of TP53 alterations in advanced NSCLC patients treated with EGFR, ALK and ROS1 tyrosine kinase inhibitors: An update;Tumor Biology;2023-10-12